ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth

P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma

(2015) Gabriel G. Vega et al.   BMC CANCER

CD79B limits response of diffuse large B cell lymphoma to ibrutinib

(2015) Joo Hyun Kim et al.   LEUKEMIA & LYMPHOMA

Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy

(2015) Seha Park et al.   Journal of Geriatric Oncology

Ibrutinib for the treatment of Waldenström macroglobulinemia

(2015) Rajshekhar Chakraborty et al.   Expert Review of Hematology

Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC

(2015) Xuan Zhou et al.   Oncotarget

A novel benzothiazole derivative SKLB826 inhibits human hepatocellular carcinoma growth via inducing G2/M phase arrest and apoptosis

(2015) Qian Lei et al.   RSC Advances

Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors

(2015) Lidan Zhang et al.   RSC Advances

Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5)

(2015) Morgane Mounier et al.   Lancet Haematology

SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo

(2014) Yong Xia et al.   CANCER LETTERS

EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma

(2014) Shu-Bin Gao et al.   MOLECULAR CANCER RESEARCH

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

(2014) S. K. Knutson et al.   MOLECULAR CANCER THERAPEUTICS

EZH2: biology, disease and structure-based drug discovery

(2013) Jin-zhi Tan et al.   ACTA PHARMACOLOGICA SINICA

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

(2013) Shivani Garapaty-Rao et al.   CHEMISTRY & BIOLOGY

Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

(2013) Hyun Jung Lee et al.   LEUKEMIA & LYMPHOMA

Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer

(2013) Woo Kyun Bae et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Chromatin proteins and modifications as drug targets

(2013) Kristian Helin et al.   NATURE

EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer

(2012) Kyung Hyun Yoo et al.   International Journal of Biological Sciences

Aberrations of EZH2 in Cancer

(2011) A. Chase et al.   CLINICAL CANCER RESEARCH

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

(2011) Francesco Crea et al.   Molecular Cancer

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE